CClinicalTrials.gg
CompletedNCT01690936MEALUpdated May 30, 2013

Metabolic Effects of Almond in the Longer-term Study

An interventional study of Almonds 43g/day in Obesity, sponsored by Purdue University. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-30.

Sponsored by Purdue University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Identifying snacks that do not contribute to positive energy balance is crucial in weight management. The satiating effects of almonds, coupled with their convenience and palatability make them a promising weight management aid. Therefore, this study aimed to examine the effects of almond consumption with meals versus snacks on outcomes such as appetite, energy intake, body weight, as well as blood glucose, insulin and lipid responses.

Read the detailed description

Experiment protocol and measurements

i) Oral glucose tolerance test (OGTT) sessions

At baseline, participants attended a session where a standard OGTT with drinks containing 75 grams dextrose was performed following an overnight fasting. Serum glucose and insulin concentrations were measured at 0 and 120 minutes of the session. During the same session, height, weight (Tanita), body fat (air displacement plethysmography, BOD POD), waist circumference, and blood pressure were measured. Participants also completed a 24-hour dietary recall using a multi-pass interview method and standard questionnaires that assessed personality, eating behavior and habitual physical activity levels during the OGTT session. After the completion of this session, participants were asked to record their hourly appetite sensations, measured as "hunger", "fullness" and "desire to eat" on visual analog scales, during waking hours for a day before attending the next (clinical) visit. Participants repeated this session after four weeks of almond consumption.

ii) Acute feeding sessions

Within a week following the OGTT session, participants returned for an acute-feeding session, after an overnight fasting of at least 10 hours. This session began between 7:00 am and 8:00 am, and lasted for approximately 515 minutes. Upon arrival, an indwelling arm catheter was placed in the upper arm for blood sample collection. Participants rested for 15 minutes after catheter placement, before a baseline blood sample was drawn. Immediately after the first blood sample collection, a standard breakfast was served, and participants were instructed to consume the entire portion within 10 minutes. Subsequent blood samplings were performed at 15, 45, 60, 90, 120, 180, and 240 minutes after the breakfast, before a standard lunch was provided to the participants. Again, participants were given 10 minutes to consume the lunch, before blood samples were taken at similar intervals again (at 265, 295, 310, 340, 370, 430, and 490 minutes of the session). Participants randomized into the BF and LN groups received 43 grams of almonds together with their meals, while the MS and AS groups consumed 43 grams of almonds 120 minutes after breakfast and lunch respectively. Participants also recorded their "hunger", "fullness", and "desire to eat" sensations when blood samples were taken. During the acute-feeding session, activities that may alter appetite sensations (e.g. sleeping and watching movies containing food cues) were prohibited. Postprandial glucose, insulin and triacylglycerol concentrations were measured for all 15 samples collected from each participant. Participants in all almond groups group were also asked to rate their likings for the almonds they ingested using a general label magnitude scale, and their action responses to almonds using the "food action rating scale", a visual analog scale ranging from "I would eat the almonds only if I were forced to" to "I would eat this food every opportunity I had" anchored to the 2 extremes. This session was repeated again after four weeks of almond supplementation.

iii) Weekly follow-ups

Following the baseline acute-feeding session, participants were asked to consume 43 grams of almonds every day at times based on their group randomization. The CL group was instructed to avoid all nuts and seeds in the diet during the study period. All almonds were dry-roasted and lightly salted, and were pre-weighed and per-packaged for convenience. Except for the permission to adjust dietary intake due to almond supplement, participants were asked to maintain their dietary intakes and physical activity levels. A ruse (breath analysis) was introduced in order to enhance the compliance of participants to consuming almonds at the designated times of day. Compliance to almond consumption was assessed through fasting plasma α-tocopherol. Participants attended weekly visit (week-1, 2 and 3) after an overnight fasting, during which body weight was recorded and compliance to study protocol reinforced. During the week-2 visit, participants were also asked to complete a 24-hour dietary intake assessment using the multi-pass interview method and appetite sensation ratings on VAS at every waking hour for a day. On week-4, participants returned for OGTT and acute-feeding sessions as described above. The study protocol was approved by the Purdue University Institutional Review Board.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Almonds
  • Body weight
  • Snacking
03

In context

Body Weight

1,223 studies on the registry are indexed under Body Weight; 131 are open to participants now.

This study's enrollment of 150 is above the median of 64 across 947 interventional studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

Purdue University is the lead sponsor of 168 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Not taking any medication known to affect glycemia, lipid metabolism or appetite
  • Regular breakfast consumers
  • Eat at least 5 meals a day
  • Weight stable
  • Either one of the 6 conditions
  • BMI 27-35
  • Family history of diabetes
  • Fasting glucose between 6.1-6.9 mmol/L
  • 2-hour glucose 7.8-11.1 mmol/L
  • blood pressure >130/85 mmHg
  • Waist >102cm (men) and >88cm (women)

Exclusion criteria

Exclusion Criteria:

  • Nut allergy
  • Not willing to eat test foods and almonds
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Breakfast

    Almonds (43g/day) were consumed with breakfast for four weeks.

    Dietary Supplement: Almonds 43g/day

  • Experimental
    Morning snack

    Almonds (43g/day) were consumed alone as morning snacks for four weeks.

    Dietary Supplement: Almonds 43g/day

  • Experimental
    Lunch

    Almonds (43g/day) were consumed with lunch for four weeks.

    Dietary Supplement: Almonds 43g/day

  • Experimental
    Afternoon snack

    Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.

    Dietary Supplement: Almonds 43g/day

  • No intervention
    Control no nuts

    Avoided all nuts and seeds

Interventions

  • Dietary supplementAlmonds 43g/day

    43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period

06

What researchers measure

Primary outcomes

  1. Postprandial glucose, insulin and lipids

    Responses of these parameters to a standard breakfast and a standard lunch for all participants, plus almonds at designated times according to group randomization.

    Time frame: 490 minutes

  2. Anthropometric measurements

    Changes in body weight, BMI, fat mass, waist circumference over 4 weeks

    Time frame: 4 weeks

  3. Fasting blood biochemistries

    Fasting glucose, insulin and lipids at baseline, week-1, 2, 3 and 4

    Time frame: 4 weeks

  4. Dietary intake

    Dietary intakes were assessed at baseline, week-2, and week-4 of study

    Time frame: 4 weeks

Secondary outcomes

  1. Blood pressure

    Blood pressure measurements at baseline and final week of study

    Time frame: Baseline and week-4

  2. Appetite ratings

    Time frame: Baseline, week-2, and week-4

  3. Postprandial appetite sensations

    Time frame: 490 minutes

07

Study locations

1 site
  • Purdue University
    West Lafayette, Indiana 47907, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01690936
Lead sponsor
Purdue University
Collaborators
Almond Board of California
Responsible party
Richard Mattes (Distinguished Prof Foods and Nutrition, Purdue University) — Principal investigator
First posted
Sep 24, 2012
Start date
Oct 2010
Primary completion
Jun 2012
Completion
Jun 2012
Last update
May 30, 2013

Study contacts

Richard D Mattes, PhD
principal investigator · Purdue University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion